Ticagrelor doubts: inaccuracies uncovered in key studies for AstraZeneca’s billion dollar drug Post date 20 June 2025 ← Rethinking approaches to analysis of global randomised controlled trials → The drug industry’s crimes and misdemeanours extend far beyond overpricing in the US